The President & CEO of Catalyst Biosciences Inc is Exercising Options

By Carrie Williams

Today, the President & CEO of Catalyst Biosciences Inc, USMAN NASSIM, exercised options of Catalyst Biosciences Inc for $407.

In addition to USMAN NASSIM, 2 other CBIO executives reported Buy trades in the last month.

Based on Catalyst Biosciences Inc’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $318K and GAAP net loss of $5.75 million. In comparison, last year the company earned revenue of $271K and had a GAAP net loss of $4.14 million. The company has a one-year high of $37 and a one-year low of $3.11. Currently, Catalyst Biosciences Inc has an average volume of 120.5K.

Starting in June 2016, CBIO received 14 Buy ratings in a row. Six different firms, including B.Riley FBR and Chardan Capital, currently also have a Buy rating on the stock.

In the last 30 days, insiders have sold $2.19M worth of CBIO shares and purchased $680 worth of CBIO shares.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant. It also develops Anti-C3 CB 2782 for dry age-related macular degeneration. The company was founded on August 5, 2002 and is headquartered in South San Francisco, CA.